Rosetta Capital
Direct secondary investments in life sciences and medical device companies across Europe and North America.
- Venture capital
- Oxford
- Type
- Venture capital
- Based in
- Oxford
- Stages
- Series A, Series B+, Growth
- Sector focus
- Healthtech, Biotech & Life Sciences, Hardware & Robotics
- Cheque size
- Above €3M
- Fund size
- Undisclosed
- Founded
- 2001
- Website
- rosettacapital.com
Rosetta Capital is a life sciences and medtech investor with offices near Oxford, in Haddenham, and in Fitzrovia, London. Its website gives 2001 as its founding year.
The firm specialises in direct secondary transactions, buying stakes in venture-backed healthcare companies from existing investors or corporations that want liquidity. It says it has made more than 50 venture investments this way over two decades, across North America and Europe, in biotechnology, pharmaceuticals and medical devices. Several holdings have reached IPO or trade-sale exits, mostly on NASDAQ and European exchanges. As a secondaries buyer it typically enters at Series A and later rather than leading first rounds.
Team
- Jonathan Hepple, Managing Partner LinkedIn
← All investors · Is this your organisation? Request an update
More investors in the directory
FirstPartyCapital
Specialist investor in AI, data and outcomes-based technology for the marketing and advertising sector
Elbow Beach
Early-stage investor in British clean technologies that cut emissions while improving customer economics
Selvedge Venture
Pre-seed to Series A investor in biotech and data-driven start-ups tackling age-related disease
SFV
Seed to Series B investor in urban, energy and industrial infrastructure technology
Zinal Growth
Growth investor partnering with founders building generational technology companies
Rockley Group
Invests in and advises technology businesses focused on sustainability, energy and resource efficiency
Subscribe to Newsletter
Join me on this exciting journey as we explore the boundless world of web design together.